Addyi, marketed as the 'female Viagra,' was approved over a decade ago amid controversy, but it has proven to be only marginally effective with significant side effects. Despite lobbying efforts and expanded indications for older women, the drug's actual benefits are minimal, with only a slight increase in satisfying sexual events, and it remains a poor choice compared to other medications. The article criticizes the drug's approval process and marketing tactics, emphasizing that it is not a safe or effective solution for female sexual desire issues.
Eli Lilly is in advanced negotiations to acquire Ventyx Biosciences for over $1 billion, which would expand Lilly's portfolio to include treatments for inflammatory bowel diseases and other conditions, with an announcement expected soon.
Novo Nordisk launches the first oral GLP-1 pill for weight loss in the U.S., offering a more affordable and accessible alternative to injections, with prices ranging from $149 to $299 per month, and aims to capture a significant share of the growing obesity treatment market.
Pfizer's stock, trading under $25, appears undervalued due to recent struggles, but its pipeline, strategic acquisitions, and solid dividend make it a potential long-term buy, despite not being among the Motley Fool's top stock picks.
The article explores the impact of Ozempic, a medication for diabetes and weight management, on the workplace, suggesting it may influence employee health and productivity. However, access to the full content requires a subscription.
The article discusses the recent developments in the GLP-1 drug market, highlighting Novo Nordisk's new pill and the potential of out-of-favor drug makers like Bristol Myers Squibb, Merck, and Pfizer as long-term investment opportunities due to their efforts to innovate and survive patent cliffs. Despite current setbacks, these companies are positioned for future growth, making them attractive for contrarian investors.
The article discusses the emerging trend of weight-loss drugs being marketed for pets like cats and dogs, highlighting the growing interest in veterinary weight management and the potential implications for pet health and the pharmaceutical industry.
Donald Trump and nine major pharmaceutical companies have agreed to reduce drug prices for Medicaid and cash payers, promising significant savings and increased manufacturing in the US, as part of efforts to lower US prescription medicine costs to levels seen in other wealthy nations.
Eli Lilly has reduced the cash prices of its Zepbound weight loss drug vials on its direct-to-consumer platform, making the medication more accessible amid industry price cuts and government efforts to lower drug costs. Starting at $299 per month for the initial dose, the prices are now more affordable compared to the previous $349, aiming to improve access for patients facing high list prices and limited insurance coverage.
Pfizer has acquired Metsera for up to $10 billion in a high-stakes deal to enter the obesity treatment market, aiming to recover from past struggles in this sector and boost its declining COVID-19 vaccine sales. The success of the investment remains uncertain, with Pfizer CEO Albert Bourla acknowledging the risk of overpaying if the venture fails or gaining a significant advantage if it succeeds.
Eli Lilly's stock (LLY) was upgraded following news that obesity drugs will now be covered by Medicare, potentially boosting the company's prospects in the pharmaceutical industry.
Pfizer has agreed to acquire weight-loss drug startup Metsera in a deal potentially worth over $10 billion, outbidding Novo Nordisk amid a competitive market for obesity treatments. The deal includes cash and performance-based payouts, giving Pfizer access to new obesity therapies and strengthening its position in a rapidly growing market. The transaction is expected to close after shareholder approval, with Pfizer aiming to leverage its global scale to expand obesity drug development.
Novo Nordisk and Pfizer are increasing their offers for Metsera amid a growing bidding war, highlighting intense competition in the pharmaceutical industry.
Eli Lilly's weight loss and diabetes drug tirzepatide has surpassed Merck's Keytruda as the world's best-selling medicine, driven by rapid sales growth since its approval in 2022, highlighting intense competition in the pharmaceutical market for obesity and diabetes treatments.
Merck's Q3 earnings surpassed estimates driven by strong Keytruda sales, reaching over $8 billion, while adjusting its full-year profit outlook downward due to lower tariff costs and challenges in China sales of Gardasil. The company plans to cut costs and offset revenue losses from upcoming patent expirations, with revenue guidance narrowed for 2023.
